|
1
|
Valery PC, Laversanne M and Bray F: Bone
cancer incidence by morphological subtype: A global assessment.
Cancer Causes Control. 26:1127–1139. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Meyers PA, Schwartz CL, Krailo M,
Kleinerman ES, Betcher D, Bernstein ML, Conrad E, Ferguson W,
Gebhardt M, Goorin AM, et al: Osteosarcoma: A randomized,
prospective trial of the addition of ifosfamide and/or muramyl
tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J
Clin Oncol. 23:2004–2011. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Marina N, Gebhardt M, Teot L and Gorlick
R: Biology and therapeutic advances for pediatric osteosarcoma.
Oncologist. 9:422–441. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Geller DS and Gorlick R: Osteosarcoma: A
review of diagnosis, management, and treatment strategies. Clin Adv
Hematol Oncol. 8:705–718. 2010.PubMed/NCBI
|
|
5
|
Gorlick R, Janeway K, Lessnick S, Randall
RL and Marina N: COG Bone Tumor Committee: Children's oncology
Group's 2013 blueprint for research: Bone tumors. Pediatr Blood
Cancer. 60:1009–1015. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Di Fiore R, Drago-Ferrante R, Pentimalli
F, Di Marzo D, Forte IM, Carlisi D, De Blasio A, Tesoriere G,
Giordano A and Vento R: Let-7d miRNA shows both antioncogenic and
oncogenic functions in Osteosarcoma-derived 3AB-OS cancer stem
cells. J Cell Physiol. 231:1832–1841. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Carrington JC and Ambros V: Role of
microRNAs in plant and animal development. Science. 301:336–338.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shukla GC, Singh J and Barik S: MicroRNAs:
Processing, maturation, target recognition and regulatory
functions. Mol Cell Pharmacol. 3:83–92. 2011.PubMed/NCBI
|
|
12
|
Kushlinskii NE, Fridman MV and Braga EA:
Molecular mechanisms and microRNAs in osteosarcoma pathogenesis.
Biochemistry (Mosc). 81:315–328. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Jansson MD and Lund AH: MicroRNA and
cancer. Mol Oncol. 6:590–610. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shen Y, Ye YF, Ruan LW, Bao L, Wu MW and
Zhou Y: Inhibition of miR-660-5p expression suppresses tumor
development and metastasis in human breast cancer. Genet Mol Res.
16:2017. View Article : Google Scholar
|
|
15
|
Salati S, Salvestrini V, Carretta C,
Genovese E, Rontauroli S, Zini R, Rossi C, Ruberti S, Bianchi E,
Barbieri G, et al: Deregulated expression of miR-29a-3p, miR-494-3p
and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in
CML leukemic stem cells. Oncotarget. 8:49451–49469. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Paydas S, Acikalin A, Ergin M, Celik H,
Yavuz B and Tanriverdi K: Micro-RNA (miRNA) profile in Hodgkin
lymphoma: Association between clinical and pathological variables.
Med Oncol. 33:342016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pei H, Jin Z, Chen S, Sun X, Yu J and Guo
W: MiR-135b promotes proliferation and invasion of osteosarcoma
cells via targeting FOXO1. Mol Cell Biochem. 400:245–252. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang J and Sun G: FOXO1-MALAT1-miR-26a-5p
feedback loop mediates proliferation and migration in osteosarcoma
cells. Oncol Res. 25:1517–1527. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Guan H, Tan P, Xie L, Mi B, Fang Z, Li J,
Yue J, Liao H and Li F: FOXO1 inhibits osteosarcoma oncogenesis via
Wnt/β-catenin pathway suppression. Oncogenesis. 4:e1662015.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kafchinski LA and Jones KB: MicroRNAs in
osteosarcomagenesis. Adv Exp Med Biol. 804:119–127. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gang L, Qun L, Liu WD, Li YS, Xu YZ and
Yuan DT: MicroRNA-34a promotes cell cycle arrest and apoptosis and
suppresses cell adhesion by targeting DUSP1 in osteosarcoma. Am J
Transl Res. 9:5388–5399. 2017.PubMed/NCBI
|
|
23
|
Xiao Y, Zhao Q, Du B, Chen HY and Zhou DZ:
MicroRNA-187 inhibits growth and metastasis of osteosarcoma by
downregulating S100A4. Cancer Invest. 36:1–9. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Krishnan P, Ghosh S, Wang B, Li D,
Narasimhan A, Berendt R, Graham K, Mackey JR, Kovalchuk O and
Damaraju S: Next generation sequencing profiling identifies
miR-574-3p and miR-660-5p as potential novel prognostic markers for
breast cancer. BMC Genomics. 16:7352015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Fortunato O, Boeri M, Moro M, Verri C,
Mensah M, Conte D, Caleca L, Roz L, Pastorino U and Sozzi G:
Mir-660 is downregulated in lung cancer patients and its
replacement inhibits lung tumorigenesis by targeting MDM2-p53
interaction. Cell Death Dis. 5:e15642014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Borzi C, Calzolari L, Centonze G, Milione
M, Sozzi G and Fortunato O: mir-660-p53-mir-486 Network: A new key
regulatory pathway in lung tumorigenesis. Int J Mol Sci. 18:pii:
E222. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ko YS, Cho SJ, Park J, Kim Y, Choi YJ, Pyo
JS, Jang BG, Park JW, Kim WH and Lee BL: Loss of FOXO1 promotes
gastric tumour growth and metastasis through upregulation of human
epidermal growth factor receptor 2/neu expression. Br J Cancer.
113:1186–1196. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wu Y, Elshimali Y, Sarkissyan M, Mohamed
H, Clayton S and Vadgama JV: Expression of FOXO1 is associated with
GATA3 and Annexin-1 and predicts disease-free survival in breast
cancer. Am J Cancer Res. 2:104–115. 2012.PubMed/NCBI
|
|
29
|
Maekawa T, Maniwa Y, Doi T, Nishio W,
Yoshimura M, Ohbayashi C, Hayashi Y and Okita Y: Expression and
localization of FOXO1 in non-small cell lung cancer. Oncol Rep.
22:57–64. 2009.PubMed/NCBI
|
|
30
|
Zhang H, Pan Y, Zheng L, Choe C, Lindgren
B, Jensen ED, Westendorf JJ, Cheng L and Huang H: FOXO1 inhibits
Runx2 transcriptional activity and prostate cancer cell migration
and invasion. Cancer Res. 71:3257–3267. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kim TH, Jo SW, Lee YS, Kim YJ, Lee SC, Kim
WJ and Yun SJ: Forkhead box O-class 1 and forkhead box G1 as
prognostic markers for bladder cancer. J Korean Med Sci.
24:468–473. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhang Y, Jia L, Zhang Y, Ji W and Li H:
Higher expression of FOXOs correlates to better prognosis of
bladder cancer. Oncotarget. 8:96313–96322. 2017.PubMed/NCBI
|
|
33
|
Kim SY, Ko YS, Park J, Choi Y, Park JW,
Kim Y, Pyo JS, Yoo YB, Lee JS and Lee BL: Forkhead transcription
factor FOXO1 inhibits angiogenesis in gastric cancer in relation to
SIRT1. Cancer Res Treat. 48:345–354. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhao Y, Wang Y and Zhu WG: Applications of
post-translational modifications of FoxO family proteins in
biological functions. J Mol Cell Biol. 3:276–282. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Dong T, Zhang Y, Chen Y, Liu P, An T,
Zhang J, Yang H, Zhu W and Yang X: FOXO1 inhibits the invasion and
metastasis of hepatocellular carcinoma by reversing ZEB2-induced
epithelial-mesenchymal transition. Oncotarget. 8:1703–1713.
2017.PubMed/NCBI
|
|
36
|
He W, Feng L, Xia D and Han N: MiR-374a
promotes the proliferation of human osteosarcoma by downregulating
FOXO1 expression. Int J Clin Exp Med. 8:3482–3489. 2015.PubMed/NCBI
|
|
37
|
Yang L, Peng F, Qin J, Zhou H and Wang B:
Downregulation of microRNA-196a inhibits human liver cancer cell
proliferation and invasion by targeting FOXO1. Oncol Rep.
38:2148–2154. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wei YT, Guo DW, Hou XZ and Jiang DQ:
miRNA-223 suppresses FOXO1 and functions as a potential tumor
marker in breast cancer. Cell Mol Biol (Noisy-le-Grand).
63:113–118. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zang Y, Wang T, Pan J and Gao F: miR-215
promotes cell migration and invasion of gastric cancer cell lines
by targeting FOXO1. Neoplasma. 64:579–587. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Lian R, Lu B, Jiao L, Li S, Wang H, Miao W
and Yu W: MiR-132 plays an oncogenic role in laryngeal squamous
cell carcinoma by targeting FOXO1 and activating the PI3K/AKT
pathway. Eur J Pharmacol. 792:1–6. 2016. View Article : Google Scholar : PubMed/NCBI
|
